跳至主要内容
临床试验/EUCTR2021-000627-12-IT
EUCTR2021-000627-12-IT进行中(未招募)1 期

A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY - MEADOWSPRING

F. HOFFMANN - LA ROCHE LTD.0 个研究点目标入组 1,040 人开始时间: 2021年6月18日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
1,040

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age >=18 years (regardless of weight) at the time of signing Informed Consent Form or age >=12 to <18 years (weight >=40 kg) at the time of signing Informed Consent Form (and Assent Form)
  • Ability, judged by the investigator, to comply with the study protocol
  • Patient was diagnosed with COVID-19 and enrolled in a Phase III RO7496998 (AT-527) COVID-19 study. Patients who completed all study assessments in the parent study are eligible, regardless of whether patients completed or discontinued early from the study drug
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 100
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 940

排除标准

  • Participation in an interventional study at the time of enrollment or plans to enroll in an interventional study during this study
  • Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study

研究者

相似试验